samedan logo

 
 
spacer
home > news
INDUSTRY NEWS AND PRESS RELEASES
 

European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL More>>

 
phone 01494 567 567
email medinfo@its.jnj.com
web www.janssen.com
 

SGS QUAY PHARMA RECEIVES QUEEN’S AWARD FOR INDUSTRY

Leading pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has received its Queen’s Award for Enterprise. The award was presented by the Lord Lieutenant of Clwyd, Henry Fetherstonhaugh, OBE, in a special ceremony at the company’s global headquarters in Deeside Industrial Park, Flintshire. More>>

 
phone +41 22 739 91 11
web sgs.com/
email 1 Place des Alpes P.O. Box 2152 1211 Geneva 1 Switzerland
 

Signant Partners with Loftware for Adaptive Investigational Product Labeling

Collaboration reinforces Signant's end-to-end clinical supplies management solutions and supports the complex manufacturing and distribution models inherent in modern clinical research More>>

 
phone +1 267 498 2300
email media@signanthealth.com
web https://signanthealth.com/
email 4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462
 

European Pharma Needs to Keep Manufacturing On The Continent And Become More Digitised To Stay Competitive, Say Speakers At New Event

The newly announced agenda for Connect in Pharma focuses on innovation as the foundation of a strong pharmaceutical industry in Europe More>>

 
phone +32 (0)2 740 10 70
email contactus@easyfairs.com
web www.connectinpharma.com
email Rue Saint-Lambert 135 1200 Brussels
 

Pioneering a New Era of Cell Therapy Manufacturing

Memphis facility becomes first North American CDMO to receive EMA approval for commercial allogeneic cell therapy production

Aug 09 2022: Following its successful inspection, our Memphis cell therapy manufacturing facility is paving the way in the cell and gene therapy industry as the first contract development and manufacturing organization (CDMO) in North America to be awarded a commercial GMP license to produce allogeneic cell therapy drug products from the European Medicines Agency (EMA). More>>

 
phone +1.877.CRIVER.1
email askcharlesriver@crl.com
web www.criver.com
email Charles River Laboratories International, Inc. 251 Ballardvale Street Wilmington, MA 01887
 

Sartorius to Acquire Albumedix, Strengthening its Portfolio of Innovative Advanced Therapy Solutions

Göttingen, August 8, 2022: The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. The business, founded in 1984, has more than 100 employees and is expected to generate revenue of approximately £33 million in 2022 with a significant double-digit EBITDA margin. The agreed purchase price amounts to approximately £415 million. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022. More>>

 
phone +49.551.308.0
email info@sartorius.com
web www.sartorius.com
email Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
 

Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform

09 Aug 2022, Darmstadt, Germany: Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development. This new platform enables biopharmaceutical companies to increase the speed to clinical manufacturing while reducing process development time and costs. More>>

 
phone +33 (0)5 57 960 960
email IECustomerrelations@merckgroup.com
web www.merckmillipore.com/GB/en
email 1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
 

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Cerevance to concurrently out-license one discovery-stage program

Boston, MA and Cambridge, UK – AUGUST 9, 2022: Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration. More>>

 
email info@cerevance.com
web cerevance.com/
email One Marina Park Drive Suite 1410 Boston, MA 02210
 

Jackson ImmunoResearch Announces New Range of Antibodies for Serology and Diagnostics Market

West Grove, PA – 02 August 2022: Jackson ImmunoResearch, a manufacturer of secondary antibodies and immunoreagents for the life science market, announces a new addition to its range of products for scientists developing immunoassays for the serology and diagnostics markets. JIR Mouse Monoclonal Anti-Human IgE antibodies are the latest addition to our suite of products suitable for diagnostics research and development. More>>

 
phone (800) 367-5296
email cuserv@jacksonimmuno.com
web www.jacksonimmuno.com/
email ackson ImmunoResearch Laboratories, Inc 872 West Baltimore Pike West Grove, Pennsylvania 19390
 

BioIVT Acquires Cypex, a Leading Manufacturer of Drug-Metabolizing Enzymes

Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development

Westbury, NY – August 8, 2022 – BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism. More>>

 
phone +1 516 483 1196
email customerservice@bioivt.com
web www.bioivt.com/
email PO Box 770, Hicksville, NY, 11802-0770
 
 
spacer
News and Press Releases

PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform

WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 21, 2022-- PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the GC 2400™ Platform, an advanced, automated gas chromatography (GC), headspace sampler and GC/mass spectrometry (GC/MS) solution designed to help lab teams simplify lab operations, drive precise results, and perform more flexible monitoring.
More info >>


White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement